Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Other Non-Current Assets (2021 - 2025)

Historic Other Non-Current Assets for Pharmaceuticals (CASI) over the last 5 years, with Q2 2025 value amounting to $644000.0.

  • Pharmaceuticals' Other Non-Current Assets fell 9990.69% to $644000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $644000.0, marking a year-over-year decrease of 9990.69%. This contributed to the annual value of $587000.0 for FY2024, which is 9992.34% down from last year.
  • As of Q2 2025, Pharmaceuticals' Other Non-Current Assets stood at $644000.0, which was down 9990.69% from $590.0 million recorded in Q1 2025.
  • Pharmaceuticals' 5-year Other Non-Current Assets high stood at $1.2 billion for Q2 2023, and its period low was $587000.0 during Q4 2024.
  • For the 5-year period, Pharmaceuticals' Other Non-Current Assets averaged around $362.2 million, with its median value being $2.2 million (2021).
  • As far as peak fluctuations go, Pharmaceuticals' Other Non-Current Assets tumbled by 9992.34% in 2024, and later skyrocketed by 8394558.4% in 2025.
  • Over the past 5 years, Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $2.2 million in 2021, then crashed by 51.52% to $1.1 million in 2022, then skyrocketed by 72437.88% to $766.0 million in 2023, then crashed by 99.92% to $587000.0 in 2024, then grew by 9.71% to $644000.0 in 2025.
  • Its Other Non-Current Assets stands at $644000.0 for Q2 2025, versus $590.0 million for Q1 2025 and $587000.0 for Q4 2024.